NCT05719155View on ClinicalTrials.gov

Pharmacokinetics and Safety/Tolerability of CKD-379

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

February 27, 2023

Primary Completion Date

March 23, 2023

Study Completion Date

April 10, 2023

Conditions
Type II Diabetes Mellitus
Interventions
DRUG

CKD-379

1 tablet administration under fed condition

DRUG

D759+D745+D150

3 tablet coadministration under fed condition

Trial Locations (1)

03080

Seoul National University Hospital, Seoul

Sponsors
All Listed Sponsors
lead

Chong Kun Dang Pharmaceutical

INDUSTRY

NCT05719155 - Pharmacokinetics and Safety/Tolerability of CKD-379 | Biotech Hunter | Biotech Hunter